July 1st 2025
The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).
Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.
Pegcetacoplan May Reduce Fatigue in PNH Accompanied by Anemia
Advancements in R/R Lymphoma: Bispecific Antibodies in Focus